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Abstract
Currently available rabies post-exposure prophylaxis (PEP) for use
in humans includes equine or human rabies immunoglobulins
(RIG). The replacement of RIG with an equally or more potent and
safer product is strongly encouraged due to the high costs and
limited availability of existing RIG. In this study, we identified two
broadly neutralizing human monoclonal antibodies that represent
a valid and affordable alternative to RIG in rabies PEP. Memory B
cells from four selected vaccinated donors were immortalized and
monoclonal antibodies were tested for neutralizing activity and
epitope specificity. Two antibodies, identified as RVC20 and RVC58
(binding to antigenic site I and III, respectively), were selected for
their potency and broad-spectrum reactivity. In vitro, RVC20 and
RVC58 were able to neutralize all 35 rabies virus (RABV) and 25
non-RABV lyssaviruses. They showed higher potency and breath
compared to antibodies under clinical development (namely CR57,
CR4098, and RAB1) and commercially available human RIG. In vivo,
the RVC20–RVC58 cocktail protected Syrian hamsters from a lethal
RABV challenge and did not affect the endogenous hamster
post-vaccination antibody response.
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Introduction
Rabies virus (RABV) belongs to the family Rhabdoviridae, genus
Lyssavirus, and causes acute encephalitis in mammals. Lyssaviruses
are enveloped single-stranded (-) RNA viruses which have helical
symmetry and display on the outer surface of the virion envelope
the G protein, which is the target antigen of virus-neutralizing
antibodies.
RABV is the first of fourteen lyssavirus species identified to date
(Dietzgen et al, 2011), with an additional yet unclassified putative
species named Lleida bat lyssavirus (LLEBV) (Arechiga Ceballos
et al, 2013). According to their viral genetic distances, two major
phylogroups have been defined: Phylogroup I includes the species
RABV, European bat lyssavirus type 1 (EBLV-1) and type 2 (EBLV-2),
Duvenhage virus (DUVV), Australian bat lyssavirus (ABLV), Aravan
virus (ARAV), Khujand virus (KHUV), Bokeloh bat lyssavirus
(BBLV), and Irkut virus (IRKV); Phylogroup II includes Lagos bat
virus (LBV), Mokola virus (MOKV), and Shimoni bat virus (SHIBV).
The remaining viruses, West Caucasian bat virus (WCBV) and
Ikoma lyssavirus, (IKOV) cannot be included in either of these
phylogroups and have been temporarily assigned to putative
phylogroups III and IV, respectively (Bourhy et al, 1992, 1993;
Amengual et al, 1997; Hooper et al, 1997; Badrane et al, 2001;
Kuzmin et al, 2010; Marston et al, 2012). It is currently thought that
infection with all lyssavirus species culminates in viral encephalitis
clinically indistinguishable from that caused by RABV and ulti-
mately results in human and animal deaths.
RABV is found almost ubiquitously worldwide in different
animal reservoirs, with occasional spillover events to non-reservoir
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hosts, including humans. Although almost 100% fatal following the
onset of symptoms, rabies can be controlled in the animal reservoirs
through mass vaccination and prevented through the appropriate
prophylactic treatment in humans exposed to the virus. Approxi-
mately 17 million people per year are treated after exposure to
rabies, in most cases following a bite from an infected animal. Some
59,000 people are estimated to die each year, mainly in Africa,
China, and India, and 50% of rabies cases worldwide occur in chil-
dren (Fooks et al, 2014; Hampson et al, 2015). However, the true
burden of rabies-related lyssaviruses in developing countries is
unknown and largely under-diagnosed (Mallewa et al, 2007).
In humans, rabies prevention is achieved by either pre- or post-
exposure prophylaxis. If exposed to RABV, post-exposure prophy-
laxis (PEP) is recommended to prevent the advancement of infection
and thus the clinical disease; however, it must be administered as
early as possible. According to the World Health Organization
(WHO) (World Health Organization. 2013), PEP includes the first-
aid treatment of the wound and the administration of the rabies
vaccine alone or in combination with rabies immunoglobulin (RIG)
for category II or III exposures, respectively. In particular, patients
with category III exposures should receive RIG administered into or
around the wound site and four to five doses of vaccine. Two types
of RIG are currently available for PEP: human or equine rabies
immunoglobulin (HRIG and ERIG, respectively). The dose of HRIG
recommended by the WHO is 20 IU/kg body weight (corresponding
to 20 mg/kg); for ERIG and F(ab0)2 products, the recommended
dose is 40 IU/kg body weight. Higher doses of RIGs have been
shown to reduce vaccine efficacy (Atanasiu et al, 1956, 1961, 1967;
Archer & Dierks, 1968; Sikes, 1969; Cabasso et al, 1971, 1974;
Wiktor et al, 1971; Cabasso, 1974). HRIG is widely used in devel-
oped countries and considered safer than ERIG. The high cost of
HRIG and its limited availability hamper its wide use in resource-
limited countries, particularly in Africa (Dodet and Africa Rabies
Bureau (AfroREB) 2009). Moreover, vaccine and HRIG or ERIG do
not confer protection against infection with all non-RABV lyssavirus
species, and protection is thought to be inversely related to the
genetic distance with the RABV vaccine strain (Brookes et al, 2005;
Hanlon et al, 2005; Both et al, 2012). Thus, a search for a replace-
ment to HRIG has been strongly encouraged by the WHO (World
Health Organization, 2013). To this end, mouse and human mono-
clonal antibodies have been developed in the last decade, with two
products in advanced clinical trials, namely CL184 (produced by
Crucell, based on the combination of two antibodies called CR57
and CR4098, Bakker et al, 2005; Goudsmit et al, 2006) and RAB1
(produced by Mass Biologics and Serum Institute of India, based on
a single monoclonal antibody, Sloan et al, 2007; Nagarajan et al,
2014). However, RABV isolates that are not neutralized by each of
these monoclonal antibodies have been identified (Marissen et al,
2005; Kuzimina et al, 2013). These findings highlight the challenge
to perform Phase 2 or 3 trials where the risk of monoclonal anti-
body-based PEP failures poses a serious ethical concerns. Indeed,
for the lack of broad RABV coverage, the development of CL184
was recently halted, while RAB1 in still under Phase 2 or 3 develop-
ment in India. Thus, in the selection and development of a safe and
effective monoclonal antibody-based PEP of RABV infections, it is of
paramount importance to identify neutralizing monoclonal antibod-
ies that are able to recognize G protein sequences of RABV from all
lineages. As previously described for other viral targets (Corti &
Lanzavecchia, 2013), the combination of two antibodies that bind to
different antigenic sites on the RABV G protein and are able to
broadly neutralize both RABV and non-RABV lyssavirus isolates will
significantly reduce the risk of PEP failure.
Results
Selection of rabies vaccinees and isolation of potent
RABV-neutralizing antibodies
In order to isolate broadly neutralizing antibodies against not only
RABV isolates but also non-RABV lyssaviruses, sera from 90 RABV
vaccinees were screened for the presence of high titers of antibodies
that bind to the RABV (CVS-11 isolate) G protein by ELISA (Fig 1A)
Of these, the 29 with the highest binding titers (ED50 > 50) were
tested for their ability to neutralize a panel of 12 pseudotyped lyssa-
viruses representing RABV and non-RABV lyssaviruses isolates of
phylogroup I, II, and III viruses (Fig 1B and Appendix Table S1).
HRIG Berirab was included as a reference. As expected, all samples
neutralized, albeit with variable titers, the CVS-11 isolate (RABV).
The neutralization profile of the other lyssavirus species varied
considerably in all donors tested, but in a few cases, all species were
neutralized. It was interesting to note that HRIG showed only
modest activity against non-RABV phylogroup I species and no
cross-reactivity with phylogroup II and III viruses.
Memory B cells from four vaccinees selected for the presence of
serum antibodies capable of broadly neutralizing multiple lyssavirus
species were immortalized with Epstein–Barr virus (EBV) and CpG,
as previously described (Traggiai et al, 2004). Culture supernatants
were then tested using a 384-well-based RABV (CVS-11)
pseudotyped neutralization assay on BHK-21 cells. Five hundred
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Figure 1. Selection of RABV vaccinees with broadly reactive neutralizing
antibodies.
A A panel of 90 sera were tested by ELISA for binding to RABV G protein.
Shown are the 1/ED50 values.
B Sera samples selected for high binding titers (1/ED50 > 50) values were
tested for the presence of neutralizing antibodies against a panel of 12
pseudotyped viruses. 1/ID50 values are shown. Black circles indicate HRIG
(Berirab®), and colored circles indicate the four donors selected for the
memory B-cell interrogation.
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human monoclonal antibodies were isolated for their ability to
neutralize pseudotyped CVS-11 RABV. Twenty-one human mono-
clonal antibodies were selected for their high neutralizing potency
against CVS-11 RABV pseudotyped virus, with IC90 (concentration
of antibody neutralizing 90% of viral infectivity) ranging from 0.01
to 317 ng/ml (Appendix Table S2). These antibodies used different
VH and VL genes, with a slight bias toward VH3 and VH4, carried
heavy chain complementarity-determining region 3 (H-CDR3) of dif-
ferent lengths (11–21), and had a variable load of somatic mutations
(Appendix Table S2). HRIG and three other human monoclonal anti-
bodies in clinical development (CR57, CR4098, and RAB1) were
used as a reference. As expected, all antibodies bound to the CVS-11
RABV G protein by ELISA.
In order to understand whether the cognate epitope is conforma-
tional or not, RABV G protein was run on a SDS–PAGE gel under
reducing or non-reducing conditions and probed by Western blot
with all the isolated human monoclonal antibodies. With a few
exceptions (RVB143, RVC44, and RVC68), all antibodies did not
bind to RABV G protein under reducing conditions, thus suggesting
that the epitopes recognized, in most cases, are conformational
(Appendix Table S2).
Antibody competition studies: determination of antigenic sites
on RABV G protein
Competition studies were then performed to determine the spatial
proximity of each of the conformational epitopes recognized by
the selected neutralizing monoclonal antibodies. The two reference
antibodies CR57 and CR4098 were previously shown to recognize
G protein antigenic sites I and III, respectively (Marissen et al,
2005; de Kruif et al, 2007), and were therefore used in this assay
as probes to map the specificity of the other antibodies. Results
shown in Fig 2 were used to cluster the 21 tested antibodies into
6 groups.
RVA125, RVC3, RVC20, and RVD74 antibodies were assigned to
the antigenic site I group, according to the competition with CR57
and their reciprocal competitions. Interestingly, the binding of anti-
genic site I antibodies to G protein enhanced the binding by several
non-antigenic site I antibodies. RVA122, RVA144, RVB492, RVC4,
RVC69, RVC38, and RVC58 were assigned to the antigenic site III
group, according to the competition with CR4098 and their recipro-
cal competitions. RVC58 showed only a partial competition with
CR4098 (64%) and with antibodies that bind to sites different from
site III, or I, suggesting that the RVC58 antibody recognizes a yet
undefined epitope that only partially overlaps with the one recog-
nized by CR4098. The binding of RVB181, RVC56, RVB185, RVC21,
RVB161, and RVC111 was blocked by antigenic site III antibodies,
but reciprocally, these antibodies did not block binding of several
other antigenic site III antibodies, such as CR4098, RVC4, and
RVC69. In interpreting competition results, it should be taken into
account that when two epitopes overlap, or even when the areas
covered by the arms of the two antibodies overlap, competition
should be almost complete and mutually cross-competitive. Thus,
only marked mutual cross-competition should be taken as unequiv-
ocal evidence of overlapping epitopes, since weak or one-way inhi-
bition may simply reflect a decreased affinity due to steric or
allosteric effects. Thus, the latter results suggest that these
antibodies form a third cluster that recognizes a distinct, hereafter
dubbed III.2, antigenic site. Three additional sites were further
defined and named A, B, and C. Site A is defined by the unique anti-
body RVB686, whose binding compromises the binding of the
majority of the labeled antibodies in the panel, but reciprocally
the binding of the labeled RBV686 is not blocked by any antibody in
the panel. These results might suggest that RVB686 binding induces
an allosteric effect on the G protein that compromises the binding of
most other antibodies. Site B is defined by antibody RVC44, whose
binding is not blocked by any other antibody in the panel. Similarly,
site C is defined by antibodies RVB143 and RVC68, which also
recognize a unique and distinct site as compared to all the other
antibodies.
Identification of broad-spectrum lyssavirus-
neutralizing antibodies
Twelve of the 21 antibodies were selected for testing based on their
neutralizing potency and recognition of distinct sites on the RABV G
protein. In addition, CR57, CR4098, RAB1, and Berirab (HRIG)
were included for testing against a large panel of lyssaviruses using
pseudotyped (N = 22) and infectious viruses (N = 16) covering
RABV, LBV, MOKV, DUVV, EBLV-1, EBLV-2, ABLV, IRKV, KHUV,
ARAV, SHIBV, BBLV, IKOV, and WCBV species (Fig 3A and B) (all
viruses that neutralized with an IC50 or IC90 < 10,000 ng/ml were
scored as positive).
Among the antigenic site I antibodies tested in the pseudotyped
neutralization assay (Wright et al, 2008, 2009), RVC20 showed the
largest breadth of reactivity being able to neutralize all phylogroup I
viruses tested as well as SHIBV from phylogroup II and IKOV from
CR57 16 89 90 100 99 1 -137 -188 -328 -6 -71 11 -262 -23 -29 -186 -110 -78 -62 -50 9 15 -8
RVA125 100 100 100 100 100 -4 -58 -83 -221 -6 -90 -172 -107 10 -38 -137 -157 -39 -5 16 17 20 12
RVC3 100 99 100 100 99 -22 -72 -113 -265 -19 -96 -174 -171 -7 -54 -122 -142 -80 -22 -9 8 14 4
RVC20 94 89 95 99 99 -16 -40 -64 -156 8 -93 -166 -115 13 -22 -96 -142 -25 20 26 28 36 41
RVD74 99 66 73 99 99 4 2 -112 -525 -3 -53 -106 -125 -27 40 -96 -140 -63 39 47 15 16 10
CR4098 17 -3 -10 26 4,4 100 95 88 96 99 97 98 97 99 96 87 97 67 98 -88 11 5 -10
RVA122 -3 -9 -9 -24 -6 95 100 88 100 78 97 98 100 96 95 90 96 63 98 8 20 4 4
RVA144 -10 -18 -13 -20 2 74 92 94 92 60 69 82 92 92 94 98 96 67 98 12 36 9 10
RVB492 -9 -2 -9 -23 -2 93 100 74 101 74 96 98 99 97 95 72 88 63 99 7 16 14 10
RVC4 9 12 8 15 16 100 99 92 99 101 98 98 97 101 96 94 95 72 99 10 14 15 12
RVC69 -4 -3 -9 -7 11 91 101 76 96 89 98 99 98 99 95 76 76 63 97 14 -2 16 10
RVC38 -11 9 4 14 21 95 101 87 100 93 99 100 100 101 96 87 93 72 99 37 32 20 12
RVC58 -15 4 -17 -17 6 64 97 65 97 52 80 93 94 88 95 49 84 67 97 23 14 12 4
RVB181 -7 -9 -12 15 8 22 91 61 85 78 57 76 77 99 83 15 79 66 94 7 22 2 4
RVC56 -10 2 -13 1 3 8 76 33 58 21 19 57 59 53 95 21 51 69 92 13 24 9 3
RVB185 -2 -9 -12 -7 2 25 63 70 64 10 0 -3 33 36 95 96 91 64 97 -1 -9 8 1
RVC21 -7 -5 2 1 5 31 74 94 69 46 20 34 67 93 94 96 96 66 97 8 39 7 2
RVB161 -4 -11 -9 7 4 26 62 33 38 -3 -36 -30 -9 24 85 5 86 68 94 2 -2 3 2
RVC111 -1 -2 -5 4 10 5 64 30 -17 5 -5 37 18 -6 90 27 53 73 96 13 -6 11 1
RVB686 82 43 13 74 91 86 100 37 99 66 98 100 99 94 96 3 58 74 92 99 24 23 10 A
RVC44 18 8 16 55 31 -2 6 11 -48 34 17 -66 -42 61 6 -11 -16 59 26 38 100 27 19 B
RVB143 9 -11 -3 21 8 32 43 -8 -41 -5 1 -14 1 17 15 -39 -27 1 29 8 -5 99 98
RVC68 -6 3 -16 27 5 15 20 -17 -40 5 -13 -30 -18 21 -7 -44 -45 8 10 -1 -10 98 100
Berirab 97 93 87 100 99 99 99 97 102 98 97 99 98 99 100 96 98 97 99 91 66 53 39
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Figure 2. RABV G protein antigenic site mapping using cross-
competition ELISA-based binding studies.
Monoclonal antibody cross-competition matrix performed by ELISA on the 21
isolated antibodies and two reference antibodies of known epitope specificity
(CR57 and CR4098). The percentage of binding inhibition of the biotinylated
antibodies (upper row) by the unlabeled antibodies listed in the left column is
shown. Results are classified using color shading codes with values ≥ 80% in
orange, < 80% and ≥ 50% in yellow, < 100% in light blue, and no shading for
values < 50%.
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putative phylogroup IV (Fig 3A). As a comparison, the antigenic site
I antibody CR57 did not neutralize EBLV-1, SHIBV, and IKOV
isolates. When tested on infectious viruses (Cliquet et al, 1998;
Warrell et al, 2008), RVC20 broadly neutralized most of the RABV,
DUVV, EBLV-1, EBLV-2, ABLV, and BBLV isolates tested as well as
the phylogroup II MOKV (Fig 3B). In the same analysis, CR57 did
not neutralize EBLV-1 and MOKV isolates.
Among the antigenic site III antibodies tested in the pseudotyped
neutralization assay, RVC58 potently neutralized all phylogroup I
viruses with an IC90 of < 10 ng/ml. As a comparison, the antigenic
site III antibodies CR4098 and RAB1 were less broad and potent and
were unable to neutralize most of the non-RABV tested. When
tested on infectious viruses, RVC58 potently neutralized all
phylogroup I viruses tested. In the same analysis, CR4098 and RAB1
showed a limited breadth of neutralization. Of note, antibody
RVC68 neutralized all phylogroups I and II pseudotyped viruses
tested (only WCBV was not neutralized), although with IC90 values
10- to 100-fold higher than compared to RVC20 and RVC58 (Fig 3A).
When tested on infectious viruses, antibody RVC68 was, however,
not able to effectively (i.e. IC50 < 10,000 ng/ml) neutralize all
phylogroups I and II isolates tested (Fig 3B).
Limiting the analysis of antibody breath to non-RABV lyssa-
viruses, RVC58 (antigenic site III) was able to neutralize 68% of all
non-RABV lyssaviruses tested and, remarkably, all the phylogroup I
non-RABV lyssaviruses tested (Fig 3C). In comparison, antibody
CR4098 and RAB1 neutralized only 19 and 18% of the non-RABV
lyssaviruses and 24 and 31% of phylogroup I non-RABV lyssa-
viruses, respectively. Further analysis showed that RVC20 (antigenic
site I) was able to neutralize 74 and 95% of the non-RABV
lyssaviruses and phylogroup I non-RABV lyssaviruses, respectively.
In contrast, antibody CR57 only neutralized 48 and 71% of the non-
RABV lyssaviruses and phylogroup I non-RABV lyssaviruses,
respectively. When combined, RVC58 and RVC20 covered 77 and
100% of the non-RABV lyssaviruses and phylogroup I non-RABV
lyssaviruses, respectively, while CR57 and CR4098 covered 52 and
71% of the non-RABV lyssaviruses and phylogroup I non-RABV
lyssaviruses, respectively. HRIG was also tested against the same
panel of pseudotyped and wild-type viruses and covered 26 and
38% of the non-RABV lyssaviruses and phylogroup I non-RABV
lyssaviruses.
The analysis of the neutralizing activity of antibodies RVC20 and
RVC58 and of the reference antibodies CR57, CR4098, and RAB1
was then extended to a large panel of RABV isolates (n = 35, 26
viruses and 9 pseudotyped viruses), which are representative of all
circulating lineages (i.e. American, Asian, Cosmopolitan, Africa 2,
Africa 3, and Arctic/Arctic-like lineages) (Fig 4 and Appendix
Table S3). All 35 RABV isolates were effectively neutralized by
RVC20 and RVC58 antibodies with IC50 or IC90 values ranging from
0.1 to 140 ng/ml. As a comparison, CR57, CR4098, and RAB1
neutralized all the RABV tested but with a significantly lower
potency. Similar to RVC20 and RVC58, HRIG neutralized the large
majority of RABV strains tested with a narrow range of IC50 ranging
from 1,000 to 10,000 ng/ml. Importantly, CR4098 and RAB1 showed
a broader range of IC50/IC90 values (0.7–23,600 ng/ml, 1–4,153 ng/ml,
respectively), neutralizing six and three RABV isolates, respectively,
with IC50 > 1,000 ng/ml, a concentration which is likely not to be
effective in PEP. This analysis was extended to an additional 7
RABV isolates for which we tested the ability of the antibodies to
bind to G protein-transfected cells by flow cytometry (Appendix
Table S3). All these RABV strains were recognized by RVC20 and
RVC58 (CR57 did not bind to the 09029NEP and to the RV/R3.PHL/
2008/TRa-065 and RAB1 to the 91001USA strain), thus extending
the number of isolates analyzed to 42.
Epitope mapping using antigenic site swapping in
chimeric pseudoviruses
In order to better define the epitope specificity of the 12 selected
human monoclonal antibodies, they were tested against chimeric
and mutant RABV and LBV pseudotyped viruses. In particular, the
amino acid changes K226E, K226N, G229E, and N336D found in the
previously described CR57 and CR4098 viral escape mutants
(Bakker et al, 2005; Marissen et al, 2005) were introduced into the
CVS-11G gene and the corresponding mutant pseudotyped viruses
produced. In addition, chimeric CVS-11 pseudotyped viruses, called
C1L and C3L, were generated, in which the antigenic sites I and III
residues of CVS-11 were replaced by the corresponding residues
from LBV (strain NIG56-RV1) (Fig 5A). Conversely, the antigenic
sites I and III residues of LBV were replaced by the corresponding
residues from CVS-11 to generate the chimeric LBV pseudotyped
viruses L1C and L3C, respectively. A similar approach was used for
antigenic sites IIa, IIb, and IV to produce the pseudotyped viruses,
L2aC, L2bC, C2bL, C2a2bL, L2a2bC, C4L, and L4C. In the case of
antigenic site “a”, the KG motif is conserved in LBV and so two
alanine residues were introduced in the CVS-11 virus to generate
the mutant, called LaA.
The panel of 12 selected antibodies as well as the reference anti-
bodies CR57 and CR4098 were tested at 15 lg/ml for their ability to
neutralize the 19 mutant pseudotyped viruses and compared with
the corresponding parental CVS-11 and LBV. The results of this
analysis are summarized in Fig 5B. The neutralizing activity of
CR57, RVC20, and RVC3 against CVS-11 is abolished when the
Figure 3. Neutralization of lyssaviruses by human monoclonal antibodies.
A selection of 12 human monoclonal antibodies, three reference antibodies (CR57, CR4098, and RAB1) and the polyclonal human immunoglobulins (HRIG, Berirab®) were
tested for their neutralizing activity against 13 different lyssavirus species using pseudotyped viruses or live viruses. Complete viral strain designations are shown in
Appendix Table S4.
A Results of neutralization assays using 22 pseudotyped viruses expressed as inhibitory concentration 90 (IC90).
B Results of neutralization assays using 15 live viruses expressed as inhibitory concentration 50 (IC50).
C Summary of the percentage of non-RABV lyssavirus isolates and phylogroup I non-RABV lyssavirus isolates neutralized with IC50 (for viruses) or IC90 (for pseudotyped
viruses) below 10,000 ng/ml for RVC20, RVC58, CR57, CR4098, and RAB1 monoclonal antibodies, HRIG or a combination of RVC20 with RVC58 or CR57 with CR4098.
Color coding indicates the potency, with IC90 (for pseudotyped viruses) or IC50 (for viruses) < 100 ng/ml in red shading, 100 ng/ml < IC50 < 1,000 ng/ml in orange
shading, and IC50 ≥ 1,000 ng/ml in yellow shading. IC50 > 10,000 ng/ml were scored as negative. *HRIG was scored as negative when IC50 or IC90 was > 100,000 ng/ml;
**RAB1 was tested against 20 pseudotyped viruses and 9 viruses.
◀
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antigenic site I from LBV is swapped into CVS-11 (mutant C1L).
While LBV was not neutralized by these antibodies, the chimeric
LBV pseudotyped virus L1C carrying the CVS-11 antigenic site I was
neutralized by CR57, RVC20, and RVC3. These results are in agree-
ment with the competition results shown in Fig 2 and confirm
that RVC20 and RVC3 recognize an epitope in the antigenic site I
of RABV G protein. When CR4098 and all the other remaining anti-
bodies in the panel were tested against C1L and L1C chimeric
pseudotyped viruses, their neutralizing activity was not altered
compared to the parental CVS-11 and LBV viruses, thus confirming
that the antigenic site I is not part of their epitope. Finally, CR57
and RVC20 antibodies (but not RVC3) were unable to neutralize the
CR57 CVS-11 escape mutants K226E, K226N, and G229E. These
results indicate that RVC3 recognizes an epitope in antigenic site I
which is distinct from that recognized by CR57 and that RVC20
recognizes an epitope overlapping with that recognized by CR57.
However, the finding that RVC20 has a broader reactivity against
non-RABV lyssaviruses (Fig 3) compared to CR57 indicates that the
RVC20 antibody may recognize a more conserved epitope.
Similarly, the neutralizing activity of CR4098, RVA122, RVA144,
RVB185, RVC21, RVC58, and RVC111 against CVS-11 is abolished
when antigenic site III from LBV is swapped into CVS-11 (mutant
C3L). While LBV was not neutralized by the antigenic site III and
III.2 antibodies, the chimeric LBV pseudotyped virus L3C carrying
the CVS-11 antigenic site III was neutralized efficiently by CR4098,
RVA144, RVB185, and RVC21. These results indicate that antibod-
ies RVA144, RVB185, and RVC21 recognize an epitope which is
similar to that recognized by CR4098. In the case of the RVC38
antibody, the swapping of antigenic site III from LBV into CVS-11
(C3L) did not affect its neutralizing activity but, similar to the
other antigenic site III antibodies described above, the L3C pseudo-
typed virus is neutralized by RVC38. This finding suggests that the
recognition of antigenic site III residues by the RVC38 antibody is
sufficient to neutralize the chimeric LBV but also that its epitope in
RABV CVS-11 is formed by additional residues surrounding anti-
genic site III. Finally, in the case of RVA122, RVC58, and RVC111
antibodies, the swapping of antigenic site III residues into LBV
resulted in partial or complete loss of neutralizing activity, thus
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Figure 4. RVC20 and RVC58 potently neutralize multi-lineage RABV isolates.
A Neutralization of RABV isolates by the selected RVC20 and RVC58 antibodies from our panel, the reference CR57, CR4098, and RAB1 antibodies and HRIG. Tested using
pseudotyped viruses (filled circles, n = 9; shown are IC90 values) or live viruses (empty circles, n = 26; shown are the IC50 values). The dotted line indicates a threshold
for neutralization above 1,000 ng/ml. The geometric mean value for each data set is shown. The P-values of Wilcoxon matched-pairs signed-rank tests are shown.
B Phylogenetic tree of 2,215G protein sequences retrieved from public databases. Highlighted with red dots are the 40 sequences of the RABV viruses tested in this work
(the G protein sequence of CV9.13 strain, was not available and was therefore not included in the tree).
Source data are available online for this figure.
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suggesting that their epitopes comprise additional residues to those
of antigenic site III.
Finally, all antibodies, including CR4098, but with the exception
of RAB1 (data not shown), RVC111 and RVC68, were able to neutral-
ize the CR4098 CVS-11 escape mutants N336D, thus indicating that
this mutation does not block the binding of these antibodies to their
cognate epitopes in the context of the CVS-11G protein. These results
indicate that some antibodies, such as RVA144, RVB185, and RVC21,
recognize an epitope in antigenic site III that is similar to that recog-
nized by CR4098, while others, such as RVC58, RVB492, RVC38, and
RVC111 recognize distinct epitopes in the antigenic site III region. In
addition, all the antibodies in our panel directed against antigenic site
III, RVC58 in particular, showed a greater breadth of reactivity
against non-RABV lyssaviruses as compared to CR4098 (Fig 3). The
same approach did not lead to the definition of the epitopes recog-
nized by antigenic site B and C antibodies RVC44 and RVC68.
Analysis of the conservation of RVC20 and RVC58 epitopes within
RABV isolates
The competition results shown in Fig 2 and the results of antigenic
site swapping shown in Fig 5 indicate that RVC20 and RVC58 bind
primarily to antigenic sites I and III, respectively. We therefore
analyzed the degree of conservation of antigenic site I and III amino
acid residues in 2566 sequences from independent RABV isolates
retrieved from multiple public databases representative of the global
RABV diversity (Fig EV2A). We found that position 231 in antigenic
site I is polymorphic (Figs 6A and EV3A). RVC20 and CR57 were
tested and neutralized lyssaviruses carrying leucine, serine, or
proline residues at position 231 that are representative of 99.69% of
the RABV analyzed (Fig EV4). Position 226 has lysine in 99.73% of
the viruses and only 0.19% of viruses carry arginine. Of note,
RVC20 but not CR57 neutralized most of the non-RABV phylogroup
I isolates carrying arginine at position 226, thus indicating that the
presence of arginine at position 226 is not always sufficient, such as
in the case of CVS-11 (Fig 5), to escape RVC20 neutralization. This
analysis indicates that the RVC20 antibody epitope is highly
conserved in RABV. Further analysis is required to investigate the
ability of RVC20 to neutralize field isolates carrying arginine at posi-
tion 226. Importantly, all three CR57 and RVC20 CVS-11 escape
mutants are neutralized efficiently by RVC58.
A similar analysis was performed for the antigenic site III anti-
body RVC58. Antigenic site III is primarily formed by residues
KSVRTWNEI (consensus sequence and positions 330–338 of the
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Figure 5. Antibodies epitope mapping using antigenic site swapping in chimeric pseudotyped viruses.
A Sequence of the CVS-11 and LBV antigenic sites I, III, IIa, IIb, IV, and a. Highlighted in gray are the residues that differ between CVS-11 and LBV.
B The scheme shows the results of neutralization of CVS-11, LBV (strain NIG56-RV1), different chimeric CVS-11 and LBV variants and different CVS-11 mutants by the
panel of 12 selected monoclonal antibodies and the reference antibodies CR57 and CR4098. Black cells indicate full neutralization, gray cells partial neutralization,
and white cells no neutralization. Strikethrough cells, not tested. Schematic showing generation of epitope swapped G protein is shown in Fig EV1.
C Side view (upper) and top view (lower) of a surface rendering of the homotrimeric prefusion structure of VSV G (PDB, 2j6j). Rabies antigenic sites, highlighted in
different colors, were superpositioned based on sequence alignment with VSV (~18% sequence identity).
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RABV G protein). As described above for antigenic site I, we there-
fore analyzed the degree of conservation of antigenic site III amino
acid residues in the panel of 2566 RABV isolates. We found that
positions 330, 331, 334, 335, and 337 are highly conserved
(> 99.61%), while residues 332, 333, 336, and 338 are polymorphic
(Figs 6B and EV3B). RVC58 recognizes RABV and non-RABV
isolates carrying multiple residues in the polymorphic positions that
are representative of at least 99.80% of the RABV analyzed
(Fig EV3B). In particular, 96.22% of RABV isolates have arginine at
position 333. Several other residues can be found at position 333,
but not aspartate, which is present in several phylogroup II viruses
that are not neutralized by RVC58. Finally, RVC58 neutralized lyssa-
viruses carrying either asparagine, aspartate, lysine, or serine at
position 336 (accounting for 99.88% of all RABV analyzed). In
contrast, RABV carrying aspartate at position 336 are poorly neutral-
ized by CR4098 and RAB1, thus indicating that approximately 4%
of the circulating RABV might be resistant to CR4098 and RAB1
neutralization. Of note, the majority (59.1%) of the African RABV
isolates analyzed carry a D at position 336 (Appendix Table S5).
These isolates correspond to lineage Africa2. This analysis con-
firmed our previous neutralization results where RVC58 neutralized
all phylogroup I lyssaviruses tested and indicated that the RVC58
epitope is highly conserved in RABV and non-RABV phylogroup I
lyssaviruses.
RVC58 and RVC20 antibodies protect Syrian hamsters from a
lethal RABV infection
To investigate whether the antibodies RVC58 and RVC20 display
neutralizing activity against a lethal RABV infection in vivo, we tested
the two antibodies in a Syrian hamster (Mesocricetus auratus) model
(Hanlon et al, 2001a). Briefly, animals (n = 12 per group) were
challenged intramuscularly with a lethal dose of RABV CVS-11 and
subsequently received post-exposure prophylaxis containing either
HRIG (PEP) or an equimolar cocktail of RVC20 and RVC58 antibodies
(exPEP) at different concentrations (0.045 or 0.0045 mg/kg).
Eleven out of 12 animals (92%) that were not treated after infec-
tion succumbed between day 6 and 8 (Fig 7A). The standard HRIG-
based post-exposure prophylaxis (PEP) was effective in reducing the
overall mortality with 8 out of 12 animals (67%) surviving the chal-
lenge. Strikingly, the combination of RVC58 + RVC20 at 0.045 mg/kg
(which corresponds to 1/440 of the administered HRIG) protected
75% of the animals (9 of 12) while a 10 times lower dose of RVC58
and RVC20 (0.0045 mg/kg) protected only 33% of the animals
(4/12). This suggests that 0.045 mg/kg RVC58 + RVC20 is equiva-
lent to the 20 mg/kg HRIG dose.
To determine the effect of the antibodies mixture on vaccine
potency, an in vivo experiment was performed in hamsters. Briefly,
vaccine immunogenicity was assessed through serological testing,
in the presence of HRIG or RVC20 and RVC58 cocktail administra-
tion. The results demonstrated that both HRIG (20 mg/kg) and
RVC58 + RVC20 (0.045 mg/kg) did not reduce the endogenous
hamster IgG-binding antibody response to the RABV G protein
(Fig 7B) as compared to animals receiving vaccine alone. Of note,
the level of neutralizing antibodies in animals administered with
antibody cocktail (both 0.045 and 40 mg/kg) is comparable to that
elicited by the vaccine alone or by the standard PEP (vaccine and
HRIG) and in most animals, the neutralizing titer is above 10 IU/ml
and never below the threshold of 0.5 IU/ml (Fig 7C). Finally, while
high levels of human antibodies (above 10 lg/ml) were found on
day 44 in animals treated with 20 mg/kg of HRIG or 40 mg/kg of
RVC58 + RVC20, undetectable or low levels of human IgG were
found in the sera of animals treated with 0.045 mg/kg of
RVC58 + RVC20 (Fig 7D). These results suggest that a dose of
0.045 mg/kg RVC58 + RVC20, which was shown to be protective in
PEP, does not compromise the production of virus-neutralizing
antibodies elicited in animals upon RABV vaccination.
Discussion
Since they were first generated in 1975 (Kohler & Milstein, 2005),
using the hybridoma technology, monoclonal antibodies have been
instrumental for a wide range of applications in research, diagnosis
and therapy of cancer, as well as in inflammatory and infectious
diseases. In this study, we interrogated the memory B-cell repertoire
of four RABV vaccines that had been pre-selected for the presence
of serum antibodies capable of broadly neutralizing multiple lyssa-
virus species. The isolation of monoclonal antibodies from human B
cells has already proven successful in the identification of several
broadly neutralizing antiviral antibodies (Corti & Lanzavecchia,
2013). These could be used as probes to identify unique epitopes for
the design of new vaccines capable of conferring a broad protection,
but also for the development of more effective and convenient anti-
gen-based diagnostic assays. The analysis of the specificity of the
panel of human neutralizing antibodies isolated in this study
unveiled a complex antigenicity of the lyssavirus glycoprotein, with
new epitopes likely involved in eliciting protective host immune
response. In addition to the two monoclonal antibodies selected for
in vivo studies (i.e. RVC20 and RVC58), we have identified several
others of interest, whose specificity and properties will require
further investigations. Of note, one of these antibodies, namely
RVC68, showed an extraordinary breadth of reactivity across
phylogroups I and II lyssaviruses and recognized a linear epitope
yet to be determined.
Behring and Kitasato pioneered the use of passive antibody ther-
apy in the early 1890s when they showed that this approach could
protect against diphtheria and tetanus (Kitasato, 1890). Although
therapy based on animal sera was shown to be effective for diphthe-
ria and other infectious diseases, their use was associated with
hypersensitivity reactions and serum sickness caused by large
amounts of animal proteins. For this reason, in several cases, such
as for cytomegalovirus, varicella zoster virus, hepatitis B virus,
and respiratory syncytial virus, the development of human
hyperimmune immunoglobulin preparations was preferred.
In the case of rabies, several animal studies in the 1930s
provided evidence that anti-rabies virus serum increased the incuba-
tion period and contributed to survival (Babes & Lepp, 1889; Habel,
1954), and subsequent studies showed that anti-rabies virus serum
combined with vaccination was more efficient than vaccination or
serum alone (Koprowski et al, 1950). To determine whether a
combination of vaccine and serum would generate similar results
in humans, the WHO Expert Committee on Rabies assessed a series
of studies for the role of serum and vaccination. The most impor-
tant study was performed in Iran in 1954 on 29 individuals bitten
by the same rabid wolf, demonstrating that the combination of
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serum and vaccine given within 2 days after exposure was clearly
more effective than vaccine alone (Baltazard & Bahmanyar, 1955;
Habel, 1957). Several subsequent studies in uninfected individuals
showed that co-administration of serum antibodies and vaccine
reduced the active endogenous humoral response (Atanasiu et al,
1967); however, booster doses of vaccine partly overcame this
interference (Wiktor et al, 1971). The mechanism of RIG action is
based on passive antibody administration, which can confer imme-
diate protection through the neutralization of rabies virus at the
site of infection, unlike vaccination where the stimulation of protec-
tive immunity is delayed. However, an active immune response
stimulated by the vaccine can then be developed in the absence of
spread of the virus to the CNS. Although no definitive protective
titer is defined for all possible exposure scenarios, the achievement
of a serum-neutralizing antibody titer equal to or > 0.5 IU/ml is
considered the protective threshold to be achieved at day 14 after
the beginning of PEP and represents the endpoint of ongoing Phase
1 and 2 trials with monoclonal antibody-based PEP (Bakker et al,
2008; Manning et al, 2008). In a previous comparative study, no
significant differences in neutralizing titers elicited by vaccination
were observed when either the CR57 + CR4098 mixture or the
HRIG were administered according to a PEP protocol (Goudsmit
et al, 2006). Similarly, the RVC20 + RVC58 antibody mixture
(0.045 mg/kg) did not interfere with vaccination response in
hamsters. Additionally, we found that the neutralizing antibodies
detected in the peripheral blood of hamsters more than 40 days
after administration of either HRIG or RVC20 + RVC58 (0.045 mg/kg),
were mainly hamster antibodies derived from the endogenous
immune response (Fig 7B and D). Of note, our PEP antibody cock-
tail (0.045 mg/kg) had almost been fully cleared by the organism
about 40 days after administration, conversely to what happens
when a higher dose of immunoglobulins [either HRIG (20 mg/kg)
or RVC20 + RVC58 (40 mg/kg)] is used. As for the RVC20 + RVC58
(40 mg/kg) antibody mixture, although the endogenous response
elicited indicated that an interference between monoclonal antibod-
ies and vaccine had somehow occurred, hamsters still had a high
neutralizing titer in peripheral blood over 40 days after administra-
tion and were therefore still potentially protected against a lethal
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Figure 6. RVC20 and RVC58 target highly conserved epitopes in antigenic sites I and III.
Level of amino acid residue conservation in antigenic sites I and III as calculated by the analysis of the G protein sequences from 2,566 RABVs. Pie charts show the detailed
distribution of amino acid usage at each position. Underlined residues indicate that viruses carrying the corresponding residue in that position are neutralized by either RVC20
or RVC58.
A Frequency of amino acid residues in antigenic site I.
B Frequency of amino acid residues in antigenic site III.
Source data are available online for this figure.
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RABV challenge. This finding certainly deserves further investiga-
tions, as it has the potential to break the paradigm on which
post-exposure prophylaxis approaches are based (i.e. immediate
administration of RIG could be safely delayed, but only of one
week, if vaccine is timely administered).
The supply of HRIG is dwindling due to the difficulty in finding
human donors and its expense (approximately USD 600–1200 per
adult treatment). Indeed, only about 1 million doses of RIG
(0.7 million ERIG and 0.3 million HRIG; excluding the Chinese
domestic market) are produced and sold every year and about 60%
of the people with category III exposures do not receive RIGs
(Bourhy et al, 2009). ERIG production is also difficult due to the
disappearance of many local producers and ethical issues
(the production has been condemned by animal protection groups).
The lower safety derived from the use of ERIG was compensated
by the development of F(ab0)2 ERIG (purified pepsin-digested ERIG,
Favirab). However, the reduced half-life of F(ab0)2 products might
have contributed to a few anecdotal PEP failures (Ertl, 2009) and
related data derived from animal studies has shown that intact
immunoglobulin products are more effective for rabies PEP than
those comprising F(ab0)2 fragments (Hanlon et al, 2001b). Another
general drawback of RIGs is that most of the virus-specific antibod-
ies are non-neutralizing and only a small proportion of the many
antibodies are pathogen specific.
The transition from RIG to monoclonal antibody-based PEP was
therefore strongly recommended by the WHO with the aim to
achieve an adequate supply, a reduction in the production costs, a
reduction in adverse reaction risks, and the availability of consis-
tently active batches. In addition, since monoclonal antibodies come
in the form of a concentrated product, they can be more effective
than RIG at wound infiltration and therefore reduce the introduction
of excess volume at the site of intramuscular injection. Another
advantage may derive from formulation studies to develop mono-
clonal antibodies in highly stable formats (e.g. lyophilized) that
would allow long-term storage as well as more convenient supply to
rural areas. According to WHO recommendations, the best approach
to replace RIG with monoclonal antibodies is based on the develop-
ment of a cocktail of antibodies able to reduce the risk of PEP fail-
ure. The best characteristics for a cocktail of RABV-neutralizing
antibodies are as follows: (i) high potency, (ii) recognition of
distinct non-overlapping antigenic sites, and (iii) high breadth of
reactivity for complete coverage of field RABV isolates. Another
important feature is that the activity of the antibodies forming the
cocktail should not rely on a synergistic effect. Indeed, although
synergy may result in potent neutralization of a virus harboring all
epitopes of the individual cocktail antibodies, this potency could be
significantly reduced for a virus in which any of these epitopes is
not available. Importantly, the RVC20 and RVC58 antibodies did not
show any synergistic neutralizing activity in vitro (Appendix Figure
S1).
In this study, we selected two human monoclonal antibodies
(RVC58 and RVC20) from vaccinees for their ability to bind to two
distinct antigenic sites (sites I and III) on the RABV G protein. In
addition to this, they were able to potently neutralize each RABV
isolate in our panel, representing all lineages, and all phylogroup I
non-RABV isolates. Indeed, the identification of rare, broadly reac-
tive antibodies such as those selected in this study can increase the
barrier to the occurrence of resistance since they can cope with a
higher degree of variability in their cognate epitopes. In this regard,
it is important to note that viral escape mutants might have an
impaired in vivo fitness and this might particularly be the case for
viral escape from multiple, broadly reactive antibodies. An addi-
tional important feature of RVC20 and RVC58, similar to HRIG, is
their ability to neutralize all the RABV tested within a narrow and
similar range of antibody concentrations, in contrast to CR57,
CR4098, and RAB1. In previous studies, it was found that the anti-
genic site I CR57 antibody was not able to neutralize 2 out of 26
viruses tested and that from the analysis of a database of 229
isolates ~1% contained mutations that would most likely abrogate
binding of CR57 (Bakker et al, 2005; Marissen et al, 2005). In the
case of the antigenic site III CR4098 antibody, it was found that in a
database of 123 RABV isolates 5 out of 123 (4%) harbored the
N336D mutation (Bakker et al, 2005). While none of the RABV
isolates carried mutations in both the CR57 and CR4098 epitopes,
the existence of naturally occurring strains resistant to one of the
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Figure 7. RVC20 and RVC58 antibodies protect Syrian hamsters from
lethal RABV infection.
A Percent survival in Syrian hamsters infected with RABV CVS-11 isolate and
then left untreated or treated with the standard PEP (HRIG and
vaccination) or with two experimental PEP protocols replacing HRIG with
different doses of a cocktail of RVC20 and RVC58 monoclonal antibodies
(and vaccination). Kaplan–Meier survival curves are shown by plotting
percent survival against time (in days). Mantel–Cox test performed to
compare treated groups versus untreated group.
B Titers of hamster IgG antibodies binding to G protein measured in sera
collected 42 days after immunization. The P-value of a Mann–Whitney test
comparing the vaccine alone group with all others is shown.
C RABV-neutralizing antibodies measured in sera collected 42 days after
immunization.
D Residuals human IgG antibodies measured in sera collected 42 days after
immunization.
Data information: Box and whiskers plot (B-C): box containing 50% with
median and whiskers minimum to maximum values.
Source data are available online for this figure.
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two antibodies in the cocktail (1–4%, with higher frequency in
endemic areas in Africa, which has the second highest number of
cases after Asia) poses a higher risk of in vivo selection of mutants
able to escape from the second antibody, thus leading to a potential
risk of PEP failure. In the case of the RAB1 antibody, currently being
tested in a Phase 2/3 trial in India as a single antibody, two out of
25 isolates tested were not neutralized and three were poorly
neutralized (Sloan et al, 2007). In this case the risk of PEP failure is,
at least in principle, higher than in the case of the CR57 and CR4098
antibody cocktail. These and our results suggest that CR4098 and
RAB1 have a limited breadth of reactivity toward non-RABV isolates
and that a significant fraction of the RABV isolates tested are not or
only poorly neutralized by these antigenic site III antibodies. It is
also important to note that the analysis of different HRIG prepara-
tions revealed that not all RABV are covered. In particular, a
comparison of Imogam HRIG (Sanofi) and BayRab (Bayer) showed
that one RABV strain of bat origin was neutralized by BayRab HRIG,
but not by the Imogram HRIG (Goudsmit et al, 2006). Our results,
as well as results from other studies (Brookes et al, 2005; Hanlon
et al, 2005; Horton et al, 2010), showed that HRIG has a limited effi-
cacy toward non-RABV isolates. Another advantage of replacing
HRIGs with a cocktail of two broadly neutralizing antibodies is
represented by the possibility to use them in the PEP of phylogroup
I non-RABV isolates. Finally, the high in vitro potency of RVC20 and
RVC58 antibodies and the in vivo results presented in this study
demonstrated that only a limited amount of these antibodies is
needed to protect from lethal infection (equivalent to ~3 mg for a
70 kg adult). Considering the marked reduction in antibody
production costs (Kelley, 2009), this amount would be compatible
with a considerably lower price (e.g., 1–10 US dollar) for GMP-grade
antibodies as compared to that of HRIGs.
In conclusion, the combination of the RVC20 and RVC58 antibod-
ies represents a treatment with an unprecedented breadth and
potency for the development of a low-risk and affordable product to
replace RIGs in rabies PEP.
Materials and Methods
Isolation of monoclonal antibodies
IgG+ memory B cells were isolated from cryopreserved PBMC using
CD22 microbeads (Miltenyi Biotec), followed by depletion of cells
carrying IgM, IgD, and IgA by cell sorting, and immortalized with
EBV and CpG in multiple replicate wells as previously described
(Traggiai et al, 2004). Culture supernatants were tested for their
ability to neutralize CVS-11 RABV pseudotyped virus infection in a
micro-neutralization assay. Positive cultures were collected and
expanded. From positive cultures, the VH and VL sequences were
retrieved by RT–PCR. RVC20 and RVC58 antibodies were cloned
into human IgG1 and Ig kappa or Ig lambda expression vectors
(kindly provided by Michel Nussenzweig, Rockefeller University,
New York, NY, USA) essentially as described (Tiller et al, 2008).
Monoclonal antibodies were produced from EBV-immortalized B
cells or by transient transfection of 293 Freestyle cells (Invitrogen).
Supernatants from B cells or transfected cells were collected and IgG
were affinity purified by Protein A or Protein G chromatography (GE
Healthcare) and desalted against PBS.
Production of pseudotyped viruses and neutralization assay
Human embryonic kidney 293T clone 17 cells (HEK 293T/17;
ATCC CRL-11268) were used for production of the lentiviral pseu-
dotypes. Neutralization assays were undertaken on BHK-21 cells
clone 13 (ATCC CCL-10). In a 384-well plate, pseudotyped virus
that resulted in an output of 50–100 × 104 relative light units
(RLU) was incubated with doubling dilutions of sera or antibodies
for 1 h at 37% (5% CO2) before the addition of 3,000 BHK-21
cells. These were incubated for a further 48 h, after which super-
natant was removed and 15 ll SteadyLite reagent (Perkin Elmer)
was added. Luciferase activity was detected 5 min later by read-
ing the plates on a Synergy microplate luminometer (BioTek)
(Wright et al, 2008). The reduction of infectivity was determined
by comparing the RLU in the presence and absence of antibodies
and expressed as percentage of neutralization. The neutralization
potency for the monoclonal antibodies is here measured as IC90,
which was defined as the antibody concentration at which RLU
were reduced 90% compared with virus control wells after subtrac-
tion of background RLU in cell control wells (ID50 for the sera, that
is the dilution of sera at which RLU were reduced 50%). ID50
values for the sera correspond to the dilution at which RLU were
reduced 50%. Antigenic site swapping between the CVS-11 (acces-
sion no. EU352767) and LBV.NIG56-RV1 (accession no. EF547431)
G genes was undertaken using overlapping PCR (Heckman & Pease,
2007) and confirmed by sequence analysis. The resulting G genes
were subsequently used to generate pseudotyped viruses and
titrated on BHK cells to ensure the mutations did not affect the
binding and entry function of the G proteins.
Binding assay
A standard ELISA was used to determine binding of serum antibod-
ies or monoclonal antibodies to RABV G protein (CVS-11). Briefly,
ELISA plates were coated with RABV G protein at 5 lg/ml, blocked
with 10% FCS in PBS, incubated with sera or human antibodies,
and washed. Bound antibodies were detected by incubation with
AP-conjugated goat anti-human IgG (Southern Biotech). Plates were
then washed, substrate (p-NPP, Sigma) was added and plates were
read at 405 nm. The relative affinities of sera binding or monoclonal
antibody binding were determined by measuring the dilution of sera
(ED50) or the concentration of antibody (EC50) required to achieve
50% maximal binding at saturation.
Western blot analysis
Purified RABV G protein (prepared according to Meslin et al,
1996) was loaded on a 12% Tris–glycine polyacrylamide gel. Protein
transfer on a PVDF membrane was performed with the iBlot blotting
system from Invitrogen. PVDF membrane was blocked for 30 min
with 10% non-fat dry milk in TBS–Tween. Incubation with primary
antibodies against G protein was performed at 0.5 lg/ml in TBS–
Tween overnight at 4°C. PVDF was washed three times with TBS–
Tween and incubated for 1 h at RT with HRP-conjugated anti-
human IgG antibody (GE Healthcare). PVDF membrane was washed
three times with TBS–Tween and positive bands detected using ECL
PlusTM Western Blotting Detection Reagent (GE Healthcare) and the
LAS4000 CCD camera system.
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ELISA competition assay
CR57, CR4098, and all 21 antibodies selected were labeled with
biotin and tested by ELISA in a matrix competition assay, in which
unlabeled antibodies were incubated first at a concentration of
25 lg/ml on RABV G protein-coated plates, followed by the addition
of a limiting concentration of biotinylated antibodies whose binding
was revealed with alkaline phosphatase-conjugated streptavidin.
When interpreting competition results, it should be taken into
account that if two epitopes overlap, or the areas covered by the
arms of the two antibodies overlap, competition should be almost
complete. Weak inhibitory or enhancing effects may reflect a
decrease in affinity owing to steric or allosteric effects.
Lyssavirus cell adaptation and in vitro neutralization assays
Selected RABVs and non-RABV lyssaviruses were initially cultured
on Neuro-2A cells (ATCC cat n. CCL-131) and further adapted on
BSR cells (a clone of BHK-21). Two protocols slightly modified from
fluorescent antibody virus neutralization (mFAVN) and from rapid
fluorescent foci inhibition (mRFFIT) test (Cliquet et al, 1998;
Warrell et al, 2008), respectively, were applied to test the potency
of antibodies under study. CVS-11 working stock was amplified and
titrated on either BSR or BHK-21, according to the neutralization test
adopted, RFFIT or FAVN, respectively. In addition, standard FAVN
and RFFIT assays were undertaken to assess the potency of tested
antibodies against CVS-11. Briefly, mFAVN assays were based on
standard FAVN but were undertaken on BSR cells.
RNA extraction, RT–PCR and sequencing
Sequencing of complete G gene of the original specimens as well
as of the cell-adapted lyssaviruses used as challenge viruses in the
in vitro assays was obtained. Viral RNA was extracted using the
Nucleospin RNA II kit, according to the manufacturer’s instruc-
tions (Macherey–Nagel GmbH & Co., Du¨ren, Germany). Briefly,
one hundred microliters of sample suspension were used for the
extraction, and RNA was eluted in a final volume of 60 ll and
stored at 80°C. One-step RT–PCR amplification was performed
using the Qiagen OneStep RT–PCR kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s instructions. Primers
used for the amplification of complete G gene sequences are avail-
able upon request. PCR products were analyzed for purity and size
by electrophoresis in 2% agarose gel after staining with GelRedTM
Nucleic Acid Gel Stain (Biotium, Hayward, CA). Amplicons were
subsequently purified with ExoSAP-IT (USB Corporation, Cleve-
land, OH) and sequenced in both directions using the Big Dye
Terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA). The products of the sequencing reactions were
cleaned up using the Performa DTR Ultra 96-well kit (Edge BioSys-
tems, Gaithersburg, MD) and analyzed on a 16-capillary ABI
PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).
RABV sequences analysis
The occurrence of different amino acid identities at antigenic site I
and antigenic site III was analyzed by downloading all RABV
glycoprotein sequences present in National Center for Biotechnology
Information (NCBI) Entrez Protein database (Sayers et al, 2009) as
of November 25, 2014. The retrieved sequences were purged of
those missing the complete sequence from amino acid positions
200–400 (covering Antigenic sites I and III) or containing ambiguous
amino acid identities or lacking the country of origin for a total of
2,566 sequences. These sequences (including the 38 sequences of
the RABV tested in our panel) were aligned using MAFFT (Katoh &
Standley, 2013) to perform the amino acid distribution analysis. All
algorithms are written in Java. A Multiple sequence alignment of
amino acid sequences was performed on the full length 2,215
sequences (480 amino acid residues in length) using Clustal omega
(Sievers & Higgins, 2014). Phylogenetic analysis of these sequences
was then undertaken using the maximum likelihood method avail-
able in the PhyML package (Guindon & Gascuel, 2003). This analy-
sis utilized the LG model of amino acid replacement with a gamma
distribution of among-site rate variation.
Ethical statement
Blood samples were collected from participants vaccinated against
rabies. All donors gave written informed consent for research use of
blood samples, following approval by the Cantonal Ethical Commit-
tee of Cantone Ticino, Switzerland. Animal studies were performed
in strict accordance with the relevant national and local animal
welfare bodies [Convention of the European Council no. 123 and
National guidelines (Legislative Decrees 116/92 and 26/2014)]. The
protocol was authorized by the Italian Ministry of Health (Decrees
128/2011-B and 115/2014-PR) before experiments were initiated
and approved by the Committee on the Ethics of Animal
Experiments of the IZSVe.
Animal studies
All experiments were performed on female SPF Syrian hamsters
(Mesocricetus auratus) of 6–7 weeks of age (average weight 105 g)
(Charles River Laboratories). Animals were housed in individually
HEPA-filtered ventilated cages, three individuals per cage, at a
temperature of 22  1°C, on a 12L:12D light cycle, with free access
to water and food. Pressed cotton pads, mouse houses, and litter
bags were used as environmental enrichment, and the standard
rodent feed was weekly integrated with autoclaved sunflower seeds.
In order to minimize the effect of subjective bias during allocation,
animals were randomly assigned to treatment or control groups. No
blinding of investigator was implemented. No samples nor animals
were excluded from the analyses.
Post-exposure prophylaxis of Syrian hamsters
Forty-eight Syrian hamsters were challenged at day 0 by the intra-
muscular route (gastrocnemius muscle in the right hind limb) with
0.05 ml of a 1:100 (106.76 MICLD50/ml) dilution of the CVS-11
strain. Animals were given biologics or PBS (negative control) by
the end of day 0. For each treated group (n = 12), a commercial
vaccine [Rabipur; Novartis Vaccines and Diagnostics, a purified
chick embryo cell vaccine containing inactivated rabies virus (strain
flury LEP), potency ≥ 2.5 International Units (IU)] was administered
intramuscularly (i.m.) in the left hind limb at days 0, 3, 7, 14, and
EMBO Molecular Medicine Vol 8 | No 4 | 2016 ª 2016 Humabs BioMed SA
EMBO Molecular Medicine A potent anti-rabies monoclonal antibody cocktail Paola De Benedictis et al
418
Published online: March 18, 2016 
28 post-infection (p.i.). Hyperimmune treatment consisted of HRIG
(Berirab, 20 mg/kg, equivalent to 20 IU/kg) or candidate antibod-
ies (0.045 mg/kg and 0.0045 mg/kg) of an equimolar mixture of
RVC20 and RVC58 antibodies administered i.m. on day 0 in the right
hind limb in a final volume of 50 ll. Challenged animals were
observed twice a day and promptly euthanized at the onset of one
of clinical signs of rabies (i.e. motoric deficit, lack of coordination,
paresis, paralysis, sensory dullness). Central nervous system (CNS)
tissues, namely brain, cerebellum, brainstem and spinal cord, were
collected to confirm rabies virus infection by means of a standard
technique, fluorescent antibody test (FAT) (OIE World Organization
for Animal Health. 2013).
Vaccine immunogenicity in non-challenged Syrian hamsters
treated with the monoclonal antibodies cocktail
Forty-eight Syrian hamsters were divided in four groups (n = 12 per
group) and vaccinated with a commercial purified chicken embryo
cell vaccine (Rabipur; Novartis Vaccines and Diagnostics, a puri-
fied chick embryo cell vaccine containing inactivated rabies virus,
strain flury LEP, potency ≥ 2.5 IU). Vaccine was administered on
day 0, 3, 7, 14, and 28 i.m. in the left hind limb. Three groups were
concomitantly administered on day 0 with HRIG (Berirab, 20 mg/kg)
or an equimolar mixture of RVC20 and RVC58 at 0.045 or 40 mg/kg
(referred as HD) that were injected i.m. in the right hind limb
and in the right and left hind limbs for HD antibody cocktail admin-
istration. Sera were collected from all animals (n = 48) on day 44
post-vaccination (p.v.) and tested by FAVN (Cliquet et al, 1998) for
the presence of rabies neutralizing antibodies and by ELISA for the
presence of either G protein-specific hamster antibodies or residual
human IgGs.
Statistics
The number of individuals in each experimental group (n = 12 per
group) was calculated using Fisher’s exact conditional test for two
proportions (as implemented by Proc Power twosamplefreq, SAS
software) and power 1-b = 0.80 (a = 0.05). A Wilcoxon matched-
pair signed-rank test was used to analyze differences in mean values
between groups. Mann–Whitney and Mantel–Cox tests were also
used as described in legends. P-values of < 0.05 were considered
statistically significant.
Expanded View for this article is available online.
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